Afficher la notice abrégée

Pharmacy Practice and Administration

dc.contributor.editorAdunlin, Georges
dc.date.accessioned2022-08-12T12:49:00Z
dc.date.available2022-08-12T12:49:00Z
dc.date.issued2022
dc.identifierONIX_20220812_9783036547305_66
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/91187
dc.description.abstractThe scope of the Special Issue is research and reviews on evaluations of current practice, innovations in medication management, developments in therapeutics, and pharmaceutical science research that informs and improves practice and administration, as well as the social and administrative pharmacy. We will mainly feature original research, reviews, short reports, and clinical studies, but also case reports, descriptive/how-to, and commentary submissions for consideration.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industriesen_US
dc.subject.otherolder adults
dc.subject.otherpolypharmacy
dc.subject.otherinternal medicine ward
dc.subject.othercommunity pharmacy
dc.subject.otherdrug disposal
dc.subject.otherunused medication
dc.subject.otherenvironment
dc.subject.otherawareness
dc.subject.otherpractice
dc.subject.otherambulatory care facilities
dc.subject.otherhealth workforce
dc.subject.otherpharmacists
dc.subject.otherTaiwan
dc.subject.otherCommonwealth Partnerships for Antimicrobial Stewardship (CwPAMS)
dc.subject.otherNational Health Service (NHS)
dc.subject.otherChief Pharmaceutical Officer’s Global Health Fellowship
dc.subject.otherCPhOGH Fellows
dc.subject.otherCwPAMS
dc.subject.otherpharmacy
dc.subject.otherfellowship
dc.subject.otherhealth partnerships
dc.subject.otherantimicrobial resistance (AMR)
dc.subject.otherglobal health
dc.subject.otherleadership
dc.subject.othernon-prescription medicines
dc.subject.otheremergency contraception
dc.subject.othercommunity pharmacies
dc.subject.otherinformation gathering
dc.subject.otheravailability
dc.subject.otherpricing
dc.subject.othermystery calls
dc.subject.otherulipristal acetate
dc.subject.otherlevonorgestrel
dc.subject.otherGermany
dc.subject.othere-prescription
dc.subject.otherprescription writing
dc.subject.otherJazan
dc.subject.otherSaudi Arabia
dc.subject.otherprescription errors
dc.subject.othermedicine consumption
dc.subject.otherdefined daily dose
dc.subject.otheradolescents and young adults
dc.subject.othercancer patients
dc.subject.otherfragility
dc.subject.otherpain
dc.subject.otherMUR
dc.subject.othermedication review
dc.subject.otherbarriers
dc.subject.otherpharmacist
dc.subject.otherpregabalin
dc.subject.otherabuse
dc.subject.othercommunity pharmacists
dc.subject.otherreproductive health
dc.subject.othercontraception
dc.subject.otheremergency contraceptives
dc.subject.otherpatient education
dc.subject.otherbiosensing technology
dc.subject.otherdigital medicine system
dc.subject.othermedication adherence
dc.subject.othermedication event monitoring system
dc.subject.othernonadherence
dc.subject.otherprescription opioids
dc.subject.othermortality
dc.subject.otherstandardized mortality ratio
dc.subject.otherunderlying cause of death
dc.subject.otherprescriptions
dc.subject.othercommunity pharmacy services
dc.subject.otheremergency prescribing
dc.subject.otherpharmacy practice
dc.subject.otherpharmacy law and regulation
dc.subject.otherCOVID-19
dc.subject.otheradditional monitoring
dc.subject.otherblack triangle
dc.subject.otheradverse event reporting
dc.subject.otherpharmacovigilance
dc.subject.otherintervention
dc.subject.otheroutcomes
dc.subject.othersystematic review
dc.subject.otherpharmacy education
dc.subject.otherdecision to study in pharmacy
dc.subject.otherselecting pharmacy as a first choice
dc.subject.otherpharmacogenomics
dc.subject.otherlearning activity
dc.subject.otherasynchronous learning
dc.subject.othervirtual learning
dc.subject.otherstudent survey
dc.subject.otherProgram of All-Inclusive Care for the Elderly
dc.subject.otheradverse drug events
dc.subject.othermedication-related problems
dc.subject.otherdrug-related problems
dc.subject.othermedication safety
dc.subject.otherMedicare
dc.subject.otherMedicaid
dc.subject.otherfinancial management
dc.subject.otherpharmacy management
dc.subject.otherbusiness
dc.subject.otherentrepreneurship
dc.subject.otherpharmacy students
dc.subject.otherperception
dc.subject.otherattitudes
dc.subject.otherability
dc.subject.otherinterprofessional
dc.subject.othersimulation
dc.subject.otheracute care
dc.subject.othernursing
dc.subject.otherstudents
dc.subject.otherstandardized patients
dc.subject.otherhigh fidelity
dc.subject.otherSPICE-R2
dc.titlePharmacy Practice and Administration
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-4729-9
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036547305
oapen.relation.isbn9783036547299
oapen.pages260
oapen.place.publicationBasel


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/